The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedyaev D.V.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education;
Research Financial Institute

Fedyaeva V.K.

Sechenov First Moscow State Medical University

Teryan R.A.

Center for Expertise and Quality Control of Medical Care

Dmitrieva U.N.

Center for Expertise and Quality Control of Medical Care

Mochalova A.A.

Center for Expertise and Quality Control of Medical Care

Pustovalov D.N.

Center for Expertise and Quality Control of Medical Care

Sodium-glucose cotransporter 2 inhibitors in chronic heart failure: impact on life expectancy in the Russian population

Authors:

Fedyaev D.V., Fedyaeva V.K., Teryan R.A., Dmitrieva U.N., Mochalova A.A., Pustovalov D.N.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2024;46(4): 20‑29

DOI: 10.17116/medtech20244604120

Read: 1033 times

Buy for 300₽
Contact the author
Table of contents

SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN CHRONIC HEART FAILURE: IMPACT ON LIFE EXPECTANCY IN THE RUSSIAN POPULATION
SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN CHRONIC HEART FAILURE: IMPACT ON LIFE EXPECTANCY IN THE RUSSIAN POPULATION

To cite this article:

Fedyaev DV, Fedyaeva VK, Teryan RA, Dmitrieva UN, Mochalova AA, Pustovalov DN. Sodium-glucose cotransporter 2 inhibitors in chronic heart failure: impact on life expectancy in the Russian population. Medical Technologies. Assessment and Choice. 2024;46(4):20‑29. (In Russ.)
https://doi.org/10.17116/medtech20244604120

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
The use of inte­llectual technologies for the medi­cal choice of professionals to work at the oil and gas ente­rprises. Russian Journal of Preventive Medi­cine. 2024;(11):13-20
Nume­rical mode­lling of defo­rmation of a filled human bladder under static load. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):5-15
Finite-element simu­lation of solar radiation impact on corpse’s cooling. Fore­nsic Medi­cal Expe­rtise. 2025;(2):31-36
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
Abstract:

OBJECTIVE

To assess the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors in chronic heart failure (CHF) on life expectancy in the Russian population.

MATERIAL AND METHODS

We used the Markov model to estimate mortality from CHF. The model considered 2 scenarios: 1) baseline scenario (standard treatment of CHF); 2) modeled scenario (treatment with SGLT2 inhibitors (dapagliflozin or empagliflozin) according to indications). Life tables were constructed to estimate life expectancy in patients with CHF and population of the Russian Federation as a whole. We estimated life expectancy increment as the difference between life expectancies in both scenarios. We performed deterministic analysis of the model’s sensitivity to variability of the main parameters.

RESULTS

By 2030, empagliflozin and dapagliflozin therapy for CHF can increase life expectancy of the Russian population by 0.085 or 0.177 years, respectively. Analysis of the model’s sensitivity to variability of the main parameters showed that overall mortality under drug therapy has the greatest impact on the modeling results. In addition, life expectancy increment depends on age of diagnosing the disease. Greater life expectancy increment is expected in younger patients undergoing therapy for CHF.

CONCLUSION

The modeled therapy with SGLT2 inhibitors (dapagliflozin and empagliflozin) for chronic heart failure increases life expectancy in the Russian Federation. Similar models for assessing the effectiveness of treatment of diseases significantly contributing to mortality can be used to justify regional and federal management decisions in healthcare.

Keywords:

life expectancy
mathematical modeling
chronic heart failure (CHF)
sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
dapagliflozin
empagliflozin

Authors:

Fedyaev D.V.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education;
Research Financial Institute

Fedyaeva V.K.

Sechenov First Moscow State Medical University

Teryan R.A.

Center for Expertise and Quality Control of Medical Care

Dmitrieva U.N.

Center for Expertise and Quality Control of Medical Care

Mochalova A.A.

Center for Expertise and Quality Control of Medical Care

Pustovalov D.N.

Center for Expertise and Quality Control of Medical Care

Received:

19.09.2024

Accepted:

15.10.2024

Close metadata

References:

  1. Drapkina OM, Boytsov SA, Omelyanovskiy VV, Kontsevaya AV, Loukianov MM, Ignatieva VI, Derkach EV. Socio-economic impact of heart failure In Russia. Rossijskij kardiologicheskij zhurnal. 2021;26(6):81-89. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4490
  2. Polyakov DS, Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Artemjeva EG, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.). https://doi.org/10.18087/cardio.2021.4.n1628
  3. Gorokhova SG, Ryazhenov VV, Pfaf VF. O bremeni serdechnoj nedostatochnosti v Rossii. Lechebnoe delo. 2014;3:42-50. (In Russ.).
  4. Dobrolyubova EI, Starostina AN. Efficiency of Regional Public Expenditure on Education and Healthcare: Evaluation from the Citizens’ Perspective. Finansovy`j zhurnal. 2022;14(4):64-78. (In Russ.). https://doi.org/10.31107/2075-1990-2022-4-64-78
  5. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oup Oxford; 2006.
  6. Oshhepkova EV, Lazareva NV, Saltykova DF, Tereshhenko SN. The first results of the Russian Registry of chronic heart failure. Kardiologiya. 2015;55(5):22-28. (In Russ.).
  7. Boytsov SA, Drapkina OM, Zayratyants OV, Kakorina EP, Samorodskaya IV. Ways to solve the problem of heart failure statistics in clinical practice. Kardiologiia. 2020;60(10):13-19. (In Russ.). https://doi.org/10.18087/cardio.2020.10.n1039
  8. McDonagh T, Metra M. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rossijskij kardiologicheskij zhurnal. 2023;28(1):117-224. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5168
  9. Lopatin YuM, Nedogoda SV, Arkhipov MV, Galyavich AS, Koziolova NA, Lozhkina NG, et al. Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. Rossijskij kardiologicheskij zhurnal. 2021;26(4):93-102.  https://doi.org/10.15829/1560-4071-2021-4368
  10. Federalnaya sluzhba gosudarstvennoj statistiki. Raspredelenie naseleniya po vozrastnym gruppam. Accessed October 31, 2024. (In Russ.). https://web.archive.org/web/20140204212420/https://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/
  11. Rossijskaya baza dannykh po rozhdaemosti i smertnosti (RosBRiS) Tsentra demograficheskikh issledovanij Rossijskoj Ekonomicheskoj Shkoly, 2023. Accessed October 31, 2024. (In Russ.). https://demogr.nes.ru/index.php/ru/demogr_indicat/data
  12. Hollenbeak RL, Fleurence CS. Rates and Probabilities in Economic Modelling. Pharmacoeconomics. 2012;25(1):1-4.  https://doi.org/10.2165/00019053-200725010-00002
  13. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019;381(21):1995-2008. https://doi.org/10.1056/NEJMoa1911303
  14. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal. 2021;42(36):3727-3738. https://doi.org/10.1093/eurheartj/ehab560
  15. Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O’Meara E, et al. Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA Cardiology. 2021;6(6):678-689.  https://doi.org/10.1001/jamacardio.2021.0379
  16. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15): 1413-1424. https://doi.org/10.1056/NEJMoa2022190
  17. Lam CSP, Ferreira JP, Pfarr E, Sim D, Tsutsui H, Anker SD, et al. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal. 2021;42(43):4442-4451. https://doi.org/10.1093/eurheartj/ehab360
  18. Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. Journal of the American College of Cardiology. 2021;78(13):1337-1348. https://doi.org/10.1016/j.jacc.2021.07.049
  19. Rebrova OYu. Klinicheskie issledovaniya: pokazateli e`ffektivnosti medicinskix texnologij, vliyayushhix na vremya do izuchaemogo soby`tiya. Medical Technologies. Assessment and Choice. 2012;8(2):10-15. 
  20. Avksentiev NA, Makarov AS, Makarova YuV, Pazukhina EM, Sisigina NN, Feoktistova OA, et al. Impact of National HIV Policy and Funding on Social and Demographic Indicators In Russia. Finansovy`j zhurnal. 2022;14(4):46-63. (In Russ.). https://doi.org/10.31107/2075-1990-2022-4-46-63
  21. Antsiferov MB, Demidov N, Tabakaev N.A. Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice. Saxarny`j diabet. 2023;26(4):328-333. (In Russ.). https://doi.org/10.14341/DM13010
  22. Safiullina AA, Uskach TM, Obraztsov IV, Akchurin RS, Saidova MA, Sapel`nikov OV, et al. Life expectancy in patients with chronic heart failure, atrial fibrillation and implantable cardiac contractility modulation devices. Russian Cardiology Bulletin. 2023;18(1):38-48. (In Russ.). https://doi.org/10.17116/Cardiobulletin20231801138
  23. Lost years of life. Accessed October 31, 2024. (In Russ.). https://ly.corp.rosmedex.ru/reasons
  24. https://doi.org/10.17116/medtech20214304128  https://doi.org/10.17116/medtech20214304128
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.